Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 21, Issue 7, 2001, Pages 1104-1117

  Pepper, Michael S ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

Cancer; Endothelium; Extracellular matrix; Metalloproteinase; Plasminogen

Indexed keywords

GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; PLASMIN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE RECEPTOR;

ANGIOGENESIS; CANCER INHIBITION; EXTRACELLULAR MATRIX; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; PROTEIN DEGRADATION; SHORT SURVEY; VASCULAR TUMOR;

EID: 0035721955     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/hq0701.093685     Document Type: Short Survey

References (169)

1. Manipulating angiogenesis: From basic science to the bedside
2. Plasminogen activators and matrix metalloproteinases in angiogenesis
3. The plasminogen activation system in tumor growth, invasion, and metastasis
4. Matrix metalloproteinases: Effectors of development and normal physiology
5. Angiogenesis: A paradigm for balanced extracellular proteolysis during cell migration and morphogenesis
6. Microscopic observations on the growth of blood capillaries in the living mammal
7. Fibrinolytic activity of reparative connective tissue
8. Basement membrane collagen: Degradation by migrating endothelial cells
9. Tumor angiogenesis: The role of oncogenes and tumor suppressor genes
10. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
11. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis
12. Vascular endothelial growth factor: Molecular and biological aspects
13. Fibroblast growth factor 2: Its structure and property, paracrine function, tumor angiogenesis, and prostate-related mitogenic and oncogenic functions
14. Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis
15. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro
16. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels
17. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo
18. Suppression of VEGF-induced angiogenesis by the protein tyrosine kinase inhibitor, lavendustin A
19. Therapeutic potentials of angiostatin in the treatment of cancer
20. Endostatin, a promising drug for antiangiogenic therapy
21. Anticancer drug targets: Approaching angiogenesis
22. Proteolytic balance and capillary morphogenesis
23. Distinct populations of basal keratinocytes express stromelysin-1 and stromelysin-2 in chronic wounds
24. Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing middle T oncogene
25. Transforming growth factor-β1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro
26. Control of type IV collagenase activity by components of the urokinase-plasmin system: A regulatory mechanism with cell-bound reactants
27. The extracellular regulation of growth factor action
28. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms
29. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells
30. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3
31. Pieces of eight: Bioactive fragments of extracellular proteins as regulators of angiogenesis
32. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
33. Endostatin, an endogenous inhibitor of angiogenesis and tumor growth
34. Anti-angiogenic cues from vascular basement membrane collagen
35. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth
36. Two RGD-independent αvβ3 integrin binding sites on tumstatin regulate distinct anti-tumor properties
37. Distinct antitumor properties of a type IV collagen domain derived from basement membrane
38. Antiangiogenic activity of restin, NC10 domain of human collagen XV: Comparison to endostatin
39. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth
40. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis
41. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin
42. The matrix metalloproteinase family
43. Matrix metalloproteinases in tumor invasion
44. Membrane-type metalloproteinases
45. Mechanisms for pro matrix metalloproteinase activation
46. Tissue inhibitors of metalloproteinases: Evolution, structure and function
47. Extracellular matrix-driven matrix metalloproteinase production in endothelial cells
48. MMP-2 colocalizes with caveolae on the surface of endothelial cells
49. Perivascular cells regulate endothelial membrane type-1 matrix metalloproteinase activity
50. Expression of matrix metalloproteinase-2 and -9 during early human wound healing
51. 72 KD and 92 KD type IV collagenase, type IV collagen, and laminin mRNAs in breast cancer: A study by in situ hybridization
52. Matrix metalloproteinases in blood vessel development in human fetal skin and in cutaneous tumors
53. Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis
54. In situ detection of matrix metalloproteinase-2 (MMP2) and the metalloproteinase inhibitor TIMP2 transcripts in human primary hepatocellular carcinoma and in liver metastasis
55. Expression of matrilysin in vascular endothelial cells adjacent to matrilysin-producing tumors
56. Comparative analysis of matrix metalloproteinases by immunocytochemistry, immunohistochemistry and zymography in human primary brain tumours
57. Matrix metalloproteinases-2 and -9, and tissue inhibitor of metalloproteinases-1 of the sheep placenta during the last third of gestation
58. Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with upgrading and myometrial invasion in endometrial carcinoma
59. Gelatinase-A (MMP-2), gelatinase-B (MMP-9), and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas
60. Expression of metalloproteinases and their inhibitors in blood vessels in human endometrium
61. Temporal expression of the matrix metalloproteinase MMP-2 correlates with fibronectin immunoreactivity during the development of the vascular system in the chick embryo chorioallantoic membrane
62. The regulation of neovascularization by matrix metalloproteinases and their inhibitors
63. Membrane-type matrix metalloproteinases in human dermal microvascular endothelial cells: Expression and morphogenetic correlation
64. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro
65. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells
66. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: Conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation
67. Endogenous basic fibroblast growth factor-dependent induction of collagenase and interleukin-6 in tumor necrosis factor-treated human microvascular endothelial cells
68. Human dermal microvascular endothelial cells produce matrix metalloproteinases in response to angiogenic factors and migration
69. Three-dimensional type I collagen lattices induce coordinate expression of matrix metalloproteinases MT1-MMP and MMP-2 in microvascular endothelial cells
70. Egr-1 mediates extracellular matrix-driven transcription of membrane type I matrix metalloproteinase in endothelium
71. Three-dimensional collagen matrices induce delayed but sustained activation of gelatinase A in human endothelial cells via MT1-MMP
72. Adhesion-dependent control of matrix metalloproteinase-2 activation in human capillary endothelial cells
73. Localization and activation of type IV collagenase/gelatinase at endothelial focal contacts
74. Complex role of matrix metalloproteinases in angiogenesis
75. Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention
76. Matrix metalloproteinases: Pro- and antiangiogenic activities
77. Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis
78. Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: Effect on in vivo mammary tumor growth and angiogenesis
79. The role of matrix metalloproteinase activity in the maturation of human capillary endothelial cells in vitro
80. Regulation of vascular growth and regression by matrix metalloproteinases in the rat aorta model of angiogenesis
81. Matrix metalloproteinase-1 and -9 activation by plasmin regulates a novel endothelial cell-mediated mechanism of collagen gel contraction and capillary tube regression in three-dimensional collagen matrices
82. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models
83. Correlation of antiangiogenic and antitumor efficacy of N-biphenylsulfonylphenylalanine hydroxamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor
84. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma
85. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9)
86. Matrix metalloproteinases generate angiostatin: Effects on neovascularization
87. Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3)
88. 1 knockout mice cause reduced tumor vascularization
89. The generation of endostatin is mediated by elastase
90. Secreted cathepsin L generates endostatin from collagen XVIII
91. Generation and degradation of human endostatin proteins by various proteinases
92. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model
93. Tumor targeting with a selective gelatinase inhibitor
94. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase 2
95. Thrombospondin type 1 repeats interact with matrix metalloproteinase 2
96. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity
97. Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2
98. Disruption of matrix metalloproteinase 2 binding to integrin αvβ3 by an organic molecule inhibits angiogenesis and tumor growth in vivo
99. Unaltered secretion of β-amyloid precursor protein in gelatinase A (matrix metalloproteinase 2)-deficient mice
100. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes
101. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice
102. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
103. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover
104. Impaired enchondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I
105. The plasminogen (fibrinolytic) system
106. Phorbol ester induces cultured endothelial cells to invade a fibrin matrix in the presence of fibrinolytic inhibitors
107. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins
108. Matrix metalloproteinase 9 protects mice from anti-glomerular basement membrane nephritis through its fibrinolytic activity
109. Transgenic mouse models in angiogenesis and cardiovascular disease
110. The response of bovine endothelial cells to FGF-2 and VEGF is dependent on their site of origin: Relevance to the regulation of angiogenesis
111. Synergistic induction of tissue-type plasminogen activator (tPA) by vascular endothelial growth factor and basic fibroblast growth factor and localization of tPA to Weibel-Palade bodies in bovine microvascular endothelial cells
112. Urokinase receptor expression on human microvascular endothelial cells is increased by hypoxia: Implications for capillary-like tube formation in a fibrin matrix
113. Hypoxia induces transcription of the plasminogen activator inhibitor-1 gene through genistein-sensitive tyrosine kinase pathways in vascular endothelial cells
114. Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells
115. Plasminogen activator inhibitor-1 is induced in migrating endothelial cells
116. Upregulation of urokinase receptor expression on migrating endothelial cells
117. Apposition-dependent induction of plasminogen activator inhibitor type-1 expression: A mechanism for balancing pericellular proteolysis during angiogenesis
118. Lymphangiogenesis and tumor metastasis: Myth or reality
119. In vitro angiogenic and proteolytic properties of bovine lymphatic endothelial cells
120. Vascular endothelial growth factor (VEGF)-C synergises with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro, and alters endothelial cell proteolytic properties
121. The regulatory effects of cytokines on lymphatic angiogenesis
122. Stimulation of plasminogen activator and inhibitor in the lymphatic endothelium
123. Impaired wound healing in mice with a disrupted plasminogen gene
124. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model
125. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure
126. Plasminogen activator (urokinase) causes vascularization of the cornea
127. Plasminogen activators (urokinase) mediate neovascularization: Possible role in tumor angiogenesis
128. In vivo angiogenic activity of urokinase: Role of endogenous fibroblast growth factor-2
129. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice
130. Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice
131. Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade
132. A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo
133. A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin
134. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization
135. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin: Implications for antiangiogenic strategies
136. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1
137. Regulation of cell adhesion by PAI-1
138. Urokinase receptor and integrin partnership: Coordination of signalling for cell adhesion, migration and growth
139. Urokinase receptor: A molecular organizer in cellular communication
140. Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1
141. Localization of tissue plasminogen activator in the endothelium of a limited number of vessels
142. In vitro angiogenesis on the human amniotic membrane: Requirement for basic fibroblast growth factor-induced proteinases
143. A role of fibrinolytic activity in angiogenesis: Quantitative assay using in vitro model
144. Indispensable role of tissue-type plasminogen activator in growth factor-dependent tube formation of human microvascular endothelial cells in vitro
145. Expression of tissue-type plasminogen activator and its inhibitor couples with development of capillary network by human microvascular endothelial cells on Matrigel
146. Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways
147. Tumor necrosis factor and epidermal growth factor modulate migration of human microvascular endothelial cells and production of tissue-type plasminogen activator and its inhibitor
148. Adenovirus-mediated expression of tissue plasminogen activator does not alter endothelial cell proliferation and invasion
149. Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation
150. Targeting of a heterologous protein to a regulated secretion pathway in cultured endothelial cells
151. Storage of tissue-type plasminogen activator in Weibel-Palade bodies of human endothelial cells
152. Posttranscriptional stimulation of endothelial cell matrix metalloproteinases 2 and 1 by endothelioma cells
153. Endothelial cells transformed by polyomavirus middle T oncogene: A model for hemangiomas and other vascular tumours
154. Endothelial cell migration and invasiveness are induced by a soluble factor produced by murine endothelioma cells transformed by polyoma virus middle T oncogene
155. Inhibition of matrix metalloproteinases by over-expression of tissue inhibitor of metalloproteinase-2 inhibits the growth of experimental hemangiomas
156. Inhibition of angiogenesis and murine hemangioma growth by Batimastat, a synthetic inhibitor of matrix metalloproteinases
157. Perturbations in the fibrinolytic pathway abolish cyst formation but not capillary-like organization of cultured murine endothelial cells
158. Urokinase-type plasminogen activator gene regulation by polyomavirus middle-T antigen
159. Human endothelial cells expressing polyoma middle T induce tumors
160. Polyoma middle T-induced vascular tumor formation: The role of the plasminogen activator/plasmin system
161. Plasminogen-dependent and -independent proteolytic activity of murine endothelioma cells with targeted inactivation of fibrinolytic genes
162. Angiogenesis: Potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation
163. Clinical studies with matrix metalloproteinase inhibitors
164. Development of matrix metalloproteinase inhibitors in cancer therapy
165. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment
166. Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis
167. Stimulation of mammary tumorigenesis by systemic tissue inhibitor of matrix metalloproteinase 4 gene delivery
168. Tumour vasculature as a target for anticancer therapy
169. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor